How should chemotherapy dosing be adjusted in a patient with significant renal or hepatic impairment?

• A. Dose reduction or schedule modification based on organ function; use pharmacology guidelines and monitor toxicity closely.
• B. Dose increase.
• C. Ignore organ function and proceed.
• D. Stop chemotherapy permanently.

Answer: (A)

Adjusting chemotherapy dosing in patients with significant renal or hepatic impairment hinges on how organ function affects drug clearance and toxicity. Many chemotherapeutic agents are eliminated by the kidneys or liver, so when these organs are impaired, drugs can accumulate, increasing the risk of severe adverse effects. The best approach is to reduce the dose or alter the dosing schedule based on the patient’s level of organ dysfunction, using pharmacology guidelines and institutional protocols. This strategy allows continued treatment while keeping drug exposure within safe limits and is paired with close monitoring for hematologic, hepatic, and renal toxicity, with further adjustments as needed.

Increasing the dose would elevate toxicity risk in the setting of organ impairment. Ignoring organ function and proceeding as if nothing were altered contradicts how pharmacokinetics change with organ failure. Stopping chemotherapy permanently is not the default; many regimens can be continued with appropriate dose modifications or temporary holds if toxicity arises, tailored to the individual patient and treatment goals.